Drug Channels News Roundup, September 2026: The 340B Margin Squeeze, Economics of Cutting List Price, Patient Adherence from Copay Cards, Negative Part D Premiums, and Drug Channel Dating Profiles

By Bryce Platt, PharmD Football season is officially back. Personally, my signal is hearing my uncle curse about bad calls from 1,000 miles away, but you may have already seen a game. This news roundup is short enough to fit into an ad break or two. *Caveat: may lead to rabbit holes that take much longer than an ad break. In this issue: The 340B squeeze from falling list prices Cutting list price to make more money Copay cards nearly double time on therapy Part D's negative premium problem Extra: A drug channel dating mismatch P.S. Join my more than…

By Bryce Platt, PharmD

Football season is officially back. Personally, my signal is hearing my uncle curse about bad calls from 1,000 miles away, but you may have already seen a game.

This news roundup is short enough to fit into an ad break or two. *Caveat: may lead to rabbit holes that take much longer than an ad break.

In this issue:

The 340B squeeze from falling list prices

Cutting list price to make more money

Copay cards nearly double time on therapy

Part D's negative premium problem

Extra: A drug channel dating mismatch

P.S. Join my more than 44,000 LinkedIn followers for valuable daily posts at 9 a.m. ET.

Drug Channels Leadership Forum 2027

Drug Channels Institute is proud to host the 2027 Drug Channels Leadership Forum, which will take place from March 15–17, 2027, in Miami. Request your invitation to this invite-only gathering of senior leaders from across the drug channel ecosystem. You must request an invitation to be considered for attendance. We will begin sending invitations in mid-October.